Veradermics, IncorporatedVeradermics raised $256.3 million in a NYSE IPO, described as the best-performing biotech IPO at the time.
Connecticut Innovations generated a record $66.5 million in cash proceeds from portfolio exits in fiscal year 2026, part of a combined $76.1 million from all investment activities. The state's strategic venture capital arm invested $59.3 million in 75 early-stage companies and venture funds, leveraging an additional $1.2 billion in outside capital. Key exits included Halda Therapeutics acquired by Johnson & Johnson for $3.05 billion, Quantum Circuits Inc. acquired by D-Wave Quantum for $550 million, and Veradermics raising $256.3 million in a NYSE IPO. CEO Matt McCooe highlighted Halda Therapeutics as the largest private biotech M&A transaction and Veradermics as the best-performing biotech IPO at the time. CI also launched its AI/Q Fund targeting commercial AI and quantum ventures, with director Gwen Cheni noting the Quantum Circuits acquisition as a milestone for the state's quantum ecosystem.
Veradermics, IncorporatedVeradermics raised $256.3 million in a NYSE IPO, described as the best-performing biotech IPO at the time.
Johnson & JohnsonJohnson & Johnson acquired Halda Therapeutics for $3.05 billion, a portfolio exit for Connecticut Innovations.
D-Wave Quantum Inc. Common StockD-Wave Quantum acquired Quantum Circuits Inc. for $550 million, a portfolio exit for Connecticut Innovations.
Halda Therapeutics was acquired by Johnson & Johnson for $3.05 billion, the largest private biotech M&A transaction.